Clinuvel Pharmaceuticals Limited EBIT

Clinuvel Pharmaceuticals Limited (CUV.AX) currently reports a EBIT of $91M as of December 2025. That compares with $84M in the prior-year period — up 8.6% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Clinuvel Pharmaceuticals Limited's EBIT history and peer comparisons.

Clinuvel Pharmaceuticals Limited's EBIT increased from $84M to $91M — a 8.6% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Clinuvel Pharmaceuticals Limited's EBIT of $91M is lower than the Healthcare sector average of $110B. That is roughly 99.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Clinuvel Pharmaceuticals Limited reported $91M in EBIT as of December 2025. That compares with $84M in the prior-year period — up 8.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $91M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Clinuvel Pharmaceuticals Limited, and consider following CUV.AX for alerts when major investors trade the stock.